Why Moderna (MRNA) Stock Fell 1.11% in 10 Minutes on Nov 12, 2026
MoveSurge measured 13 earlier Moderna headlines with an attributed reaction between Aug 14, 2026 and Nov 11, 2026. The largest was +64.73% in 15 minutes, on Aug 19, 2026.
- MRNA fell 1.11% in the 10 minutes after the 10:12:19 ET headline, from $240.00 to $237.34.
- The move kept building after the first minute: -0.48% at one minute, -1.11% at 10 minutes.
Reaction by asset (real prices)
| Asset | 2m before | At release | +1m | +10m | +1m % | +10m % |
|---|---|---|---|---|---|---|
| MRNA | 240.00 | 240.00 | 238.85 | 237.34 | -0.48% | -1.11% |
Moderna (MRNA) shares fell 1.11% in the 10 minutes after this headline reached the MoveSurge news feed at 10:12:19 ET on Thursday, November 12, 2026: “Moderna executive says company expects near-term talks with the US FDA about filing for its COVID-flu combination shot”
MRNA in the first 10 minutes
From a reference price of $240.00 just before the headline, the stock was down 0.48% after one minute and down 1.11%, at $237.34, after 10 minutes. The move kept building after the first minute.
Other MRNA headlines on November 12, 2026
- 07:21 ET: “Moderna extends its $1.5 billion Ares credit facility maturity to 2031, with $900 million in borrowing capacity available through 2029” (-0.91% in 10 minutes)
Earlier MRNA headlines and the measured reaction
MoveSurge measured 13 earlier Moderna headlines with an attributed reaction between Aug 14, 2026 and Nov 11, 2026. The largest was +64.73% in 15 minutes, on Aug 19, 2026.
- Nov 11, 2026, 16:59 ET: “MSCI says Moderna and Aritzia will join the MSCI World Index, measured by full company market capitalization” (-0.32% in 10 minutes)
- Nov 6, 2026, 06:45 ET: “Moderna says it is conducting a limited U.S. launch of its seasonal influenza vaccine for the 2026–2027 season, with approval coming after the annual contracting cycle” (+6.97% in 10 minutes)
- Nov 5, 2026, 17:24 ET: “Health Canada authorizes Moderna’s mRNA influenza and combined influenza-COVID-19 vaccines” (-3.12% in 10 minutes)
- Nov 4, 2026, 11:06 ET: “Moderna advances its investigational Bundibugyo ebolavirus vaccine toward a Phase 2/3 study” (+1.30% in 10 minutes)
- Oct 26, 2026, 15:52 ET: “Moderna (MRNA) CEO says the melanoma vaccine will be effective against additional cancers” (+0.77% in 10 minutes)
- Oct 23, 2026, 09:38 ET: “ESMO says it cannot establish whether the Moderna-Merck data leak stemmed from human error, a technical problem or another cause” (+6.41% in 10 minutes)
Moderna at a glance
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Market value | $101.49 billion (as of Nov 12, 2026) |
Prices are closes of 1-minute bars. Each move on this page is measured from the last completed bar before its headline.
What headline moved Moderna stock on November 12, 2026?
At 10:12:19 ET, this headline crossed: “Moderna executive says company expects near-term talks with the US FDA about filing for its COVID-flu combination shot”. The stock fell 1.11% in the next 10 minutes.
How far did MRNA move after the headline?
From $240.00 just before the headline to $237.34 10 minutes later, a -1.11% move.
What else has moved MRNA stock recently?
The two largest measured reactions before November 12, 2026: Nov 6, 2026, Moderna says it is conducting a limited U.S. launch of its seasonal influenza vaccine for the 2026–2027 season, with approval coming after the annual contracting cycle (+6.97% in 10 minutes); Oct 23, 2026, ESMO says it cannot establish whether the Moderna-Merck data leak stemmed from human error, a technical problem or another cause (+6.41% in 10 minutes).
Sources
-
MRNA headline and measured reaction, Nov 12, 2026
— MoveSurge
The headline as it crossed, its timestamp, and the measured price reaction reported on this page.
Never miss the next market-moving story
Follow the core market-moving feed across equities, macro, currencies and commodities. Your subscription includes price moves after the news, search, watchlists, alerts and research tools.
Go live — 7 days for $29 Watch live headlines -- free